Study of the hypoglycemic and cardioprotective effect of empagliflozin in therapy of patients with type 2 diabetes mellitus

Urunbaeva D.A., Najmutdinova D.K., Sadikova N.G., Gafurova D.S., Урунбаева Д.А., Нажмутдинова Д.К., Садикова Н.Г., Гафурова Д.С., Urunbaeva D.A., Najmutdinova D.K., Sadikova N.G., Gafurova D.S.

Research Focus · 2023-yil

Annotatsiya

According to the Algorithms for specialized care for patients with diabetes mellitus (2019), patients with type 2 diabetes and ASCVD are recommended to use iSGLT2 or glucagon-like peptide-1 receptor agonists, which have proven cardiovascular benefits, as part of hypoglycemic therapy. The study involved 42 patients with type 2 diabetes mellitus, including 21 women and 21 men, who sought advice from the 2nd therapy department at the multidisciplinary clinic of the Tashkent Medical Academy. The duration of the disease ranged from 3 to 8 years, the mean age was 56.6±9.8 years. These patients were divided into 2 groups: group 1 - 18 patients, gliclazide MB with slow release at a dose of 60 mg/day was added to metformin, group 2 included 24 patients, they were added to metformin at a dose of empagliflozin at a dose of 10 mg per day. The results showed a good hypoglycemic effect of empagliflozin with metformin compared with the control group. The drug empagliflozin has a positive effect on heart function, as evidenced by a slight increase in EF.

Maqola ma’lumotlari
MualliflarUrunbaeva D.A., Najmutdinova D.K., Sadikova N.G., Gafurova D.S., Урунбаева Д.А., Нажмутдинова Д.К., Садикова Н.Г., Гафурова Д.С., Urunbaeva D.A., Najmutdinova D.K., Sadikova N.G., Gafurova D.S.
JurnalResearch Focus
NashriyotВетеринария ИТИ ва “Илм-фан ва инновациялар академияси” МЧЖ
ISSN2181-3833
Nashr sanasi2023-02-05
Jild2
Son1
Betlar11-19
TilIngliz
Ilmiy sohaVeterinariya
DOI10.66073/researchfocus.v2i1.2819
Indeksga qo‘shilgan2026-09-12

DOI: 10.66073/researchfocus.v2i1.2819 · Maqolaning asl sahifasi

Kalit so‘zlar

type 2 diabetes mellitus, atherosclerotic cardiovascular disease, sodium glucose cotransporter type 2 inhibitors, empagliflozin, сахарный диабет 2 тип, атеросклеротические сердечно-сосудистые заболевания, ингибиторы натрий глюкозного котранспортёра типа, эмпаглифлозин, 2-toifa qandli diabet, aterosklerotik yurak-qon tomir kasalliklari, natriy glyukoza kortransporter 2 turi ingibitorlari, empagliflozin

Ilmiy soha

Veterinariya

Iqtibos keltirish

APAUrunbaeva D.A., Najmutdinova D.K., Sadikova N.G., Gafurova D.S., Урунбаева Д.А., Нажмутдинова Д.К., Садикова Н.Г., Гафурова Д.С., Urunbaeva D.A., Najmutdinova D.K., Sadikova N.G., & Gafurova D.S. (2023). STUDY OF THE HYPOGLYCEMIC AND CARDIOPROTECTIVE EFFECT OF EMPAGLIFLOZIN IN THERAPY OF PATIENTS WITH TYPE 2 DIABETES MELLITUS. Research Focus, 2(1), 11-19. https://doi.org/10.66073/researchfocus.v2i1.2819
GOST (OAK)Urunbaeva D.A. va b. STUDY OF THE HYPOGLYCEMIC AND CARDIOPROTECTIVE EFFECT OF EMPAGLIFLOZIN IN THERAPY OF PATIENTS WITH TYPE 2 DIABETES MELLITUS // Research Focus. – 2023. – T. 2, № 1. – P. 11-19. – DOI: 10.66073/researchfocus.v2i1.2819.
MLAUrunbaeva D.A., Najmutdinova D.K., Sadikova N.G., Gafurova D.S., Урунбаева Д.А., Нажмутдинова Д.К., Садикова Н.Г., Гафурова Д.С., Urunbaeva D.A., Najmutdinova D.K., Sadikova N.G., and Gafurova D.S. “STUDY OF THE HYPOGLYCEMIC AND CARDIOPROTECTIVE EFFECT OF EMPAGLIFLOZIN IN THERAPY OF PATIENTS WITH TYPE 2 DIABETES MELLITUS.” Research Focus, 2(1), 11-19, 2023. https://doi.org/10.66073/researchfocus.v2i1.2819
ChicagoUrunbaeva D.A., Najmutdinova D.K., Sadikova N.G., Gafurova D.S., Урунбаева Д.А., Нажмутдинова Д.К., Садикова Н.Г., Гафурова Д.С., Urunbaeva D.A., Najmutdinova D.K., Sadikova N.G., and Gafurova D.S. “STUDY OF THE HYPOGLYCEMIC AND CARDIOPROTECTIVE EFFECT OF EMPAGLIFLOZIN IN THERAPY OF PATIENTS WITH TYPE 2 DIABETES MELLITUS.” Research Focus, 2(1), 11-19 (2023). https://doi.org/10.66073/researchfocus.v2i1.2819
HarvardUrunbaeva D.A., Najmutdinova D.K., Sadikova N.G., Gafurova D.S., Урунбаева Д.А., Нажмутдинова Д.К., Садикова Н.Г., Гафурова Д.С., Urunbaeva D.A., Najmutdinova D.K., Sadikova N.G., and Gafurova D.S (2023) ‘STUDY OF THE HYPOGLYCEMIC AND CARDIOPROTECTIVE EFFECT OF EMPAGLIFLOZIN IN THERAPY OF PATIENTS WITH TYPE 2 DIABETES MELLITUS’, Research Focus, 2(1), 11-19. https://doi.org/10.66073/researchfocus.v2i1.2819
BibTeX
@article{urunbaevada2023,
  title = {STUDY OF THE HYPOGLYCEMIC AND CARDIOPROTECTIVE EFFECT OF EMPAGLIFLOZIN IN THERAPY OF PATIENTS WITH TYPE 2 DIABETES MELLITUS},
  author = {Urunbaeva D.A. and Najmutdinova D.K. and Sadikova N.G. and Gafurova D.S. and Урунбаева Д.А. and Нажмутдинова Д.К. and Садикова Н.Г. and Гафурова Д.С. and Urunbaeva D.A. and Najmutdinova D.K. and Sadikova N.G. and Gafurova D.S.},
  journal = {Research Focus},
  year = {2023},
  volume = {2},
  number = {1},
  pages = {11-19},
  doi = {10.66073/researchfocus.v2i1.2819},
  url = {https://doi.org/10.66073/researchfocus.v2i1.2819}
}

Boshqa maqola uchun iqtibos tayyorlash

Research Focus jurnalidan boshqa maqolalar

Research Focus — barcha maqolalar · 2023-yil arxivi

Veterinariya sohasidagi boshqa maqolalar

Veterinariya sohasidagi OAK jurnallari